Capecitabine trials for Triple Negative Breast Cancer

All Capecitabine trials · All Triple Negative Breast Cancer trials

Phase breakdown

Recruiting trials studying Capecitabine for Triple Negative Breast Cancer

• A Prospective, Phase II Trial Using ctDNA to Initiate Post-operation Boost Therapy After NAC in TNBC
  NCT04501523 · Phase: Phase 2 · Ages: 18 Years to 80 Years · Sex: Female · 1 location
• A Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer
  NCT06279364 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• A Study of Tetrathiomolybdate (TM) Plus Capecitabine
  NCT06134375 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 80 Years · Sex: All (male and female) · 3 locations
• Different Methods of Capecitabine in Patients With Non-PCR After Neoadjuvant Therapy for TNBC
  NCT06700382 · Phase: Not specified · Ages: No age limits stated · Sex: All (male and female) · 1 location
• PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBC
  NCT06245889 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Female · 2 locations
• Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
  NCT06393374 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 310 locations
• Serial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early Triple-negative Breast Cancer
  NCT04768426 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
  NCT05633654 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 356 locations
• Trial Studying Chemotherapy in Nigerian Women With Triple Negative Breast Cancer
  NCT06291064 · Phase: Phase 2 · Ages: 18 Years to 70 Years · Sex: Female · 4 locations

Common questions

How many trials study Capecitabine for Triple Negative Breast Cancer?

9 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.